? CANCER RESEARCH TRAINING AND EDUCATION COORDINATION The Center for Cancer Mentoring, Education, Leadership, and Oncology-related Training (CAMELOT) serves as the centralized hub for the Ohio State University Comprehensive Cancer Center (OSUCCC) fostering cancer research and education, and disseminating those opportunities. CAMELOT?s efforts begin at the high school level, continue through undergraduate and graduate training, and then extend through post-doctoral training and into early faculty development and mentoring. CAMELOT is directed by Dr. Lawrence Kirschner, the OSUCCC Associate Director of Training and Education. He is assisted by Drs. Deepa Sampath, Elizabeth Klein, and Rosa Lapalombella. CAMELOT coordinates training and education programs through: 1) direct programs (e.g., for high school, Pelotonia fellows, external undergraduate student summer rotations including students from Ohio Historically Black Universities and Colleges); 2) integrating College of Medicine (COM) programs with OSUCCC activities and opening them to trainees and junior faculty outside the COM; 3) supporting grant submissions by junior faculty; and 4) supporting training grant submissions. The Pelotonia Fellowship Program (PFP), a major commitment by the OSUCCC to fellowship training, has been in existence for 10 years, and provides stipends and research support to fellows from the undergraduate to the postdoctoral fellowship level. OSUCCC provides $2-3M/year to support the PFP. During the current grant cycle, 251 pre- and postdoctoral fellowships awarded, of which 155 had mentors who were OSUCCC members from all five of the OSUCCC research programs and 10 of the 15 OSU Colleges. More than 90% of these trainees are currently active as cancer researchers. New programs developed by CAMELOT include two cancer research-focused pipeline programs, one for local underrepresented minority high school students and another for current OSU undergraduates.
The Specific Aims are to: 1) provide integration and coordination of training opportunities for cancer research across the OSUCCC and university ecosystem, and region, including high schools and colleges; 2) enhance formalized programming for cancer-based mentoring including both peer-to-peer and senior-to-junior mentoring; and, 3) develop an integrated system to enable assessment and outcome tracking for trainees at all levels of engagement with the OSUCCC (grants, papers, academic positions, etc.) to foster continuous quality improvement in educational and career development activities. The OSUCCC is planning robust faculty recruitment around strategic research priorities that will create new opportunities for education and training. To accommodate this, a bigger pipeline for training is planned in the next funding cycle. The OSUCCC will: 1) expand graduate and postgraduate training slots and programs for high school students; 2) establish the Young Cancer Investigator Faculty Academy that focuses on OSUCCC wet-lab researchers to support development of independent research programs; 3) establish a uniform tracking system for trainees; and 4) foster submissions of R25 and T32 training grants, including supplements.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016058-45
Application #
10089992
Study Section
Subcommittee H - Clinical Groups (NCI)
Project Start
1997-09-12
Project End
2025-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
45
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Siegel, Marni B; He, Xiaping; Hoadley, Katherine A et al. (2018) Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer. J Clin Invest 128:1371-1383
White, Brian S; Lanc, Irena; O'Neal, Julie et al. (2018) A multiple myeloma-specific capture sequencing platform discovers novel translocations and frequent, risk-associated point mutations in IGLL5. Blood Cancer J 8:35
Owen, Dwight; Chaft, Jamie E (2018) Immunotherapy in surgically resectable non-small cell lung cancer. J Thorac Dis 10:S404-S411
O'Brien, Susan M; Jaglowski, Samantha; Byrd, John C et al. (2018) Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials. JAMA Oncol 4:712-716
Guo, Sijin; Piao, Xijun; Li, Hui et al. (2018) Methods for construction and characterization of simple or special multifunctional RNA nanoparticles based on the 3WJ of phi29 DNA packaging motor. Methods 143:121-133
Sadowski, Abbey R; Gardner, Heather L; Borgatti, Antonella et al. (2018) Phase II study of the oral selective inhibitor of nuclear export (SINE) KPT-335 (verdinexor) in dogs with lymphoma. BMC Vet Res 14:250
Barredo, Julio C; Hastings, Caroline; Lu, Xiamin et al. (2018) Isolated late testicular relapse of B-cell acute lymphoblastic leukemia treated with intensive systemic chemotherapy and response-based testicular radiation: A Children's Oncology Group study. Pediatr Blood Cancer 65:e26928
Kim, So-Youn; Nair, Devi M; Romero, Megan et al. (2018) Transient inhibition of p53 homologs protects ovarian function from two distinct apoptotic pathways triggered by anticancer therapies. Cell Death Differ :
Yadav, Marshleen; Song, Feifei; Huang, Jason et al. (2018) Ocimum flavone Orientin as a countermeasure for thrombocytopenia. Sci Rep 8:5075
Farquhar, Neil; Thornton, Sophie; Coupland, Sarah E et al. (2018) Patterns of BAP1 protein expression provide insights into prognostic significance and the biology of uveal melanoma. J Pathol Clin Res 4:26-38

Showing the most recent 10 out of 2602 publications